SGP (SpyGlass Pharma) Other Financing: $-2.67 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $25.07
View Full Analysis

What is SpyGlass Pharma Other Financing?

SpyGlass Pharma SGP -0.59% 12 Other Financing is $-2.67 Mil as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100.

SpyGlass Pharma's Other Financing for the three months ended in Jun. 2026 was $0.00 Mil.

SpyGlass Pharma's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.67 Mil.

SpyGlass Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma Other Financing Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
Other Financing
-0.24 0.00 -1.30

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial -0.26 0.00 0.00 -2.67 0.00
SGP
12GF Score
SpyGlass Pharma Inc SGP
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-2.67 Mil mean?
SpyGlass Pharma (SGP) has a Other Financing of $-2.67 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's Other Financing too high?
SpyGlass Pharma's current Other Financing is $-2.67 Mil. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Other Financing compare to RIGL and NGNE?
SpyGlass Pharma's Other Financing of $-2.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for SpyGlass Pharma and its competitors. SpyGlass Pharma's current Other Financing is $-2.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Other Financing of $-2.67 Mil. The current Other Financing is $-2.67 Mil. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Other Financing is $-2.67 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price